Geodon Labeling Changes Still Under Discussion, Pfizer Says

Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet